Skip to main content
Erschienen in: Medical Oncology 1/2013

01.03.2013 | Original Paper

Increased expression of forkhead box M1 protein is associated with poor prognosis in clear cell renal cell carcinoma

verfasst von: Xiao-Rong Wu, Yong-Hui Chen, Dong-Ming Liu, Jian-Jun Sha, Han-Qing Xuan, Juan-Jie Bo, Yi-Ran Huang

Erschienen in: Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Forkhead box protein M1 (FoxM1) is crucial in the regulation of various biological processes, including cell proliferation, organogenesis, and angiogenesis. Overexpression of FoxM1 is associated with carcinogenesis. In this study, immunohistochemistry was carried out to examine FoxM1 expression in clear cell renal cell carcinoma (ccRCC), and these data were examined for correlation with clinicopathological parameters and prognosis. FoxM1 protein had high expression in 37 of 87 cases of ccRCC (42.5 %), which was significantly higher than in normal tissues, and FoxM1 overexpression was significantly associated with tumor stage (P = 0.005) and recurrence (P = 0.027). The Kaplan–Meier survival analysis demonstrated that FoxM1 expression was significantly associated with shorter recurrence-free survival and overall survival (P = 0.007 and P = 0.008, respectively). Multivariate analysis further demonstrated that FoxM1 was an independent prognostic factor for patients with ccRCC. So FoxM1 might be a potential molecular marker to predict the prognosis of patients with ccRCC.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66.PubMedCrossRef Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43–66.PubMedCrossRef
2.
Zurück zum Zitat Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.PubMedCrossRef Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.PubMedCrossRef
3.
Zurück zum Zitat Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843–52.PubMedCrossRef Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843–52.PubMedCrossRef
4.
Zurück zum Zitat Eichelberg C, Junker K, Ljungberg B, et al. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol. 2009;55(4):851–63.PubMedCrossRef Eichelberg C, Junker K, Ljungberg B, et al. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol. 2009;55(4):851–63.PubMedCrossRef
5.
Zurück zum Zitat Belldegrun AS. Renal cell carcinoma: prognostic factors and patient selection. Eur Urol Suppl. 2007;6(7):477–83.CrossRef Belldegrun AS. Renal cell carcinoma: prognostic factors and patient selection. Eur Urol Suppl. 2007;6(7):477–83.CrossRef
6.
Zurück zum Zitat Laoukili J, Kooistra MRH, Brás A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol. 2005;7(2):126–36.PubMedCrossRef Laoukili J, Kooistra MRH, Brás A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol. 2005;7(2):126–36.PubMedCrossRef
7.
Zurück zum Zitat Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta. 2007;1775(1):92–102.PubMed Laoukili J, Stahl M, Medema RH. FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta. 2007;1775(1):92–102.PubMed
8.
Zurück zum Zitat Katoh M, Katoh M. Human FOX gene family (Review). Int J Oncol. 2004;25(5):1495–500.PubMed Katoh M, Katoh M. Human FOX gene family (Review). Int J Oncol. 2004;25(5):1495–500.PubMed
9.
Zurück zum Zitat Korver W, Roose J, Wilson A, et al. The winged-helix transcription factor Trident is expressed in actively dividing lymphocytes. Immunobiology. 1997;198(1–3):157–61.PubMedCrossRef Korver W, Roose J, Wilson A, et al. The winged-helix transcription factor Trident is expressed in actively dividing lymphocytes. Immunobiology. 1997;198(1–3):157–61.PubMedCrossRef
10.
Zurück zum Zitat Ye H, Kelly TF, Samadani U, et al. Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal cells of embryonic and adult tissues. Mol Cell Biol. 1997;17(3):1626–41.PubMed Ye H, Kelly TF, Samadani U, et al. Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal cells of embryonic and adult tissues. Mol Cell Biol. 1997;17(3):1626–41.PubMed
11.
Zurück zum Zitat Yang DK, Son CH, Lee SK, et al. Forkhead box M1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance. Hum Pathol. 2009;40(4):464–70.PubMedCrossRef Yang DK, Son CH, Lee SK, et al. Forkhead box M1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance. Hum Pathol. 2009;40(4):464–70.PubMedCrossRef
12.
Zurück zum Zitat Chan DW, Yu SY, Chiu PM, et al. Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J Pathol. 2008;215(3):245–52.PubMedCrossRef Chan DW, Yu SY, Chiu PM, et al. Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J Pathol. 2008;215(3):245–52.PubMedCrossRef
13.
Zurück zum Zitat Sun HC, Li M, Lu JL, et al. Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma. Oncol Rep. 2011;25(6):1533–9.PubMed Sun HC, Li M, Lu JL, et al. Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma. Oncol Rep. 2011;25(6):1533–9.PubMed
14.
Zurück zum Zitat Douard R, Moutereau S, Pernet P, et al. Sonic Hedgehog–dependent proliferation in a series of patients with colorectal cancer. Surgery. 2006;139(5):665–70.PubMedCrossRef Douard R, Moutereau S, Pernet P, et al. Sonic Hedgehog–dependent proliferation in a series of patients with colorectal cancer. Surgery. 2006;139(5):665–70.PubMedCrossRef
15.
Zurück zum Zitat Madureira PA, Varshochi R, Constantinidou D, et al. The Forkhead box M1 protein regulates the transcription of the estrogen receptor α in breast cancer cells. J Biol Chem. 2006;281(35):25167–76.PubMedCrossRef Madureira PA, Varshochi R, Constantinidou D, et al. The Forkhead box M1 protein regulates the transcription of the estrogen receptor α in breast cancer cells. J Biol Chem. 2006;281(35):25167–76.PubMedCrossRef
16.
Zurück zum Zitat Jiang LZ, Wang P, Deng B, et al. Overexpression of Forkhead Box M1 transcription factor and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Hum Pathol. 2011;42(8):1185–93.PubMedCrossRef Jiang LZ, Wang P, Deng B, et al. Overexpression of Forkhead Box M1 transcription factor and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Hum Pathol. 2011;42(8):1185–93.PubMedCrossRef
17.
Zurück zum Zitat Pilarsky C, Wenzig M, Specht T, et al. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia. 2004;6(6):744–50.PubMedCrossRef Pilarsky C, Wenzig M, Specht T, et al. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia. 2004;6(6):744–50.PubMedCrossRef
18.
Zurück zum Zitat Greene FL. AJCC cancer staging manual. 6th ed. New York: Springer; 2002. Greene FL. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.
19.
Zurück zum Zitat Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–63.PubMedCrossRef Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–63.PubMedCrossRef
20.
Zurück zum Zitat Yang GL, Zhang LH, Bo JJ, et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol. 2012;106(1):57–61.PubMedCrossRef Yang GL, Zhang LH, Bo JJ, et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol. 2012;106(1):57–61.PubMedCrossRef
21.
Zurück zum Zitat Li Q, Zhang N, Jia Z, et al. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res. 2009;69(8):3501–9.PubMedCrossRef Li Q, Zhang N, Jia Z, et al. Critical role and regulation of transcription factor FoxM1 in human gastric cancer angiogenesis and progression. Cancer Res. 2009;69(8):3501–9.PubMedCrossRef
22.
Zurück zum Zitat Kim IM, Ackerson T, Ramakrishna S, et al. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res. 2006;66(4):2153–61.PubMedCrossRef Kim IM, Ackerson T, Ramakrishna S, et al. The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res. 2006;66(4):2153–61.PubMedCrossRef
23.
Zurück zum Zitat Kalin TV, Wang I, Ackerson TJ, et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 2006;66(3):1712–20.PubMedCrossRef Kalin TV, Wang I, Ackerson TJ, et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 2006;66(3):1712–20.PubMedCrossRef
24.
Zurück zum Zitat Wang Z, Banerjee S, Kong D, et al. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 2007;67(17):8293–300.PubMedCrossRef Wang Z, Banerjee S, Kong D, et al. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 2007;67(17):8293–300.PubMedCrossRef
25.
Zurück zum Zitat Wang Z, Ahmad A, Li Y, et al. Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev. 2010;36(2):151–6.PubMedCrossRef Wang Z, Ahmad A, Li Y, et al. Forkhead box M1 transcription factor: a novel target for cancer therapy. Cancer Treat Rev. 2010;36(2):151–6.PubMedCrossRef
26.
Zurück zum Zitat Wang Z, Li Y, Ahmad A, et al. Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem. 2011;112(1):78–88.PubMedCrossRef Wang Z, Li Y, Ahmad A, et al. Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem. 2011;112(1):78–88.PubMedCrossRef
27.
Zurück zum Zitat Zhang Y, Zhang N, Dai B, et al. FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res. 2008;68(21):8733–42.PubMedCrossRef Zhang Y, Zhang N, Dai B, et al. FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. Cancer Res. 2008;68(21):8733–42.PubMedCrossRef
28.
Zurück zum Zitat Penzo M, Massa PE, Olivotto E, et al. Sustained NF-kappaB activation produces a short-term cell proliferation block in conjunction with repressing effectors of cell cycle progression controlled by E2F or FoxM1. J Cell Physiol. 2009;218(1):215–27.PubMedCrossRef Penzo M, Massa PE, Olivotto E, et al. Sustained NF-kappaB activation produces a short-term cell proliferation block in conjunction with repressing effectors of cell cycle progression controlled by E2F or FoxM1. J Cell Physiol. 2009;218(1):215–27.PubMedCrossRef
29.
Zurück zum Zitat Tan Y, Raychaudhuri P, Costa RH. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol. 2007;27(3):1007–16.PubMedCrossRef Tan Y, Raychaudhuri P, Costa RH. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol. 2007;27(3):1007–16.PubMedCrossRef
30.
Zurück zum Zitat Xia LM, Huang WJ, Wang B, et al. Transcriptional up-regulation of FoxM1 in response to hypoxia is mediated by HIF-1. J Cell Biochem. 2009;106(2):247–56.PubMedCrossRef Xia LM, Huang WJ, Wang B, et al. Transcriptional up-regulation of FoxM1 in response to hypoxia is mediated by HIF-1. J Cell Biochem. 2009;106(2):247–56.PubMedCrossRef
Metadaten
Titel
Increased expression of forkhead box M1 protein is associated with poor prognosis in clear cell renal cell carcinoma
verfasst von
Xiao-Rong Wu
Yong-Hui Chen
Dong-Ming Liu
Jian-Jun Sha
Han-Qing Xuan
Juan-Jie Bo
Yi-Ran Huang
Publikationsdatum
01.03.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0346-1

Weitere Artikel der Ausgabe 1/2013

Medical Oncology 1/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.